February 6th, we celebrated, together with our colleagues from Drugs for Neglected Diseases initiative - DNDi and partners, the positive opinion given by the European Medicines Agency about Fexinidazole, DNDi’s first “new chemical entity”: a breakthrough all-oral treatment that cures patients affected by sleeping sickness, a fatal yet neglected disease.
PhinC Development brought its expertise in pharmacokinetic modeling, in particular to allow the selection of the therapeutic dose and the optimization of the Fexinidazole dosage.
Indeed, it is a great honor that rewards an outstanding commun effort.
Learn more about it: https://www.prescrire.org/fr/3/31/60626/0/NewsDetails.aspx
